164 related articles for article (PubMed ID: 20690063)
1. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.
Schlomm T; Chun FKh; Erbersdobler A
Methods Mol Biol; 2010; 664():177-89. PubMed ID: 20690063
[TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
Ohori M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
[TBL] [Abstract][Full Text] [Related]
4. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
6. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract][Full Text] [Related]
11. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
12. [Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer biomarkers: a current perspective.
Kumar-Sinha C; Rhodes DR; Yu J; Chinnaiyan AM
Expert Rev Mol Diagn; 2003 Jul; 3(4):459-70. PubMed ID: 12877385
[TBL] [Abstract][Full Text] [Related]
14. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
16. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
18. Discovery of prostate cancer biomarkers by microarray gene expression profiling.
Sørensen KD; Ørntoft TF
Expert Rev Mol Diagn; 2010 Jan; 10(1):49-64. PubMed ID: 20014922
[TBL] [Abstract][Full Text] [Related]
19. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.
Talantov D; Jatkoe TA; Böhm M; Zhang Y; Ferguson AM; Stricker PD; Kattan MW; Sutherland RL; Kench JG; Wang Y; Henshall SM
J Urol; 2010 Oct; 184(4):1521-8. PubMed ID: 20723930
[TBL] [Abstract][Full Text] [Related]
20. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
